ClinicalTrials.gg
Status unknownNCT04613895Updated Nov 3, 2020

Treatment Effect According to Timing of Administration of DWP14012 40 mg

An interventional study of DWP14012 and DWP14012 in Erosive Esophagitis, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-11-03.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Esophagitis with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Esophagitis · Korea, Republic of.

Planned enrollment
9th of 12
186 · median 290
Started
2020
with 1 other
No phase
2 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
3 of 12
Daewoong Pharmaceutical Co. LTD.

Among the 12 studies in Esophagitis with a site in Korea, Republic of, this one is the 9th largest by planned enrollment, is one of 2 that started in 2020, is one of 2 with no phase, and was the 10th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

None of the 12 studies in Esophagitis with a site in Korea, Republic of is open now. The open studies under Esophagitis, anywhere →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis with a site in Korea, Republic of as a file.
02

Study summary

The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.

Read the detailed description

Subjects will provide written informed consent for study participation and then undergo appropriate screening. Subjects who meet the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to either before meal group or after meal group. Subjects will be stratified into two groups according to Los Angeles classification grades (LA grades) A/B or C/D, as determined by upper gastrointestinal (GI) endoscopy. Subjects will visit the site at Week 2 for endoscopic assessment. Subjects whose mucosal breaks have completely healed will be prematurely withdrawn and considered to have reached end of treatment. Subjects whose mucosal breaks have not healed will continue to receive IPs for an additional 2 weeks and will visit the site for endoscopic assessment at Week 4.

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between 19 and 75 years old based on the date of written agreement
  • Those who have been diagnosed with erosive esophagitis of LA Grade A-D on the upper gastrointestinal endoscopy
  • Those who experienced symptoms of heartburn or acid regurgitation within the last 7 days

Exclusion criteria

Exclusion Criteria:

  • Those who have undergone gastric acid suppression or gastric, esophageal surgery
  • Those who with liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    fed state group

    just after a meal

    Drug: DWP14012

  • Experimental
    fasted state group

    before a meal

    Drug: DWP14012

Interventions

  • DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks

    Also known as: fed state

  • DWP14012 40 mg, orally, once daily before a meal up to 4 weeks

    Also known as: fasted state

06

What researchers measure

Primary outcomes

  1. healing rate at 4 week

    Cumulative healing rate of erosive esophagitis at 4 week by endoscopy

    Time frame: 4 week

Secondary outcomes

  1. healing rate at 2 week

    Cumulative healing rate of erosive esophagitis at 2 week by endoscopy

    Time frame: 2 week

07

Study locations

1 site
  • Hanyang University Medical Center
    Seoul, 04763, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2020; primary completion for May 2021, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2020
First posted
Nov 3, 2020
StartEst.
Nov 17, 2020
Primary completionEst.
May 30, 2021
CompletionEst.
Dec 30, 2021
Last update
Nov 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04613895
Collaborators
Hanyang University
Responsible party
Sponsor
First posted
Nov 3, 2020
Start date
Nov 17, 2020 (estimated)
Primary completion
May 30, 2021 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
Nov 3, 2020

Study contacts

HOJIN LEE
Contact
hjlee200@daewoong.co.kr
+82-2-550-8651

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion